

EudraCT Number: 2008-001968-36CONSTRUCTHelpdesk@swansea.ac.uk

Centre / Hospital Name	

Participant study ID								

Please begin to complete this Case Report Form (CRF) once the participant has consented to the CONSTRUCT cohort study.

- The CRF should be completed using black ink and BLOCK CAPITALS.
- Once Section 1 has been completed, it should be detached from the rest of the CRF, faxed separately from the rest of the CRF and stored in a secure location for data protection purposes.
- RCT eligibility criteria questions are written in bold. Those responses that make the participant ineligible for the RCT are in bold and have a [X].
- Once each page has been completed, the person completing it should initial and sign their name and record the date of completion at the bottom of that page.
- Any amendments to the CRF should be done by crossing out the error once, initialling and dating that action. The new entry should be written in alongside as clearly as possible.
- If you have any queries relating to the completion of this CRF, please contact the CONSTRUCT Helpdesk by email on CONSTRUCTHelpdesk@swansea.ac.uk
- Please fax all pages in accordance with the instructions written on the relevant pages of this CRF to the CONSTRUCT Trial Office on 01792 606599.

							I		l			
Section 1a: Participant demographics												
Title:	N	⁄lr	Mrs		Miss		Ms	D	r Other	(specify)	)	
Surname:												
Forename(s):												
Date of birth:	d	d	m	m	У	У	У	У	NOT eligi	ble for th	ne RCT if	<18y [X]
Gender:		Male			Fema	ale						
NHS N°:												
Hospital N°:												
Home address:							•					
Postcode:												
Tel. No:	0											
Ethnic group:		White	е			Mixe	ed					
		Black	<			Any	other e	thnic gı	roup (spe	cify)		
		Asiar	า		-							
Section 1b:	Parti	icipa	nt's	GP	deta	ils						
GP full name:								-	GP ID o	ode: _		
Practice name:								GP	Practice of	ode: _		
Practice address:												
Practice postcode:	:											

Participant study ID

Once Section 1 has been completed, detach it, fax it to the CONSTRUCT Trial Office on 01792 606599 and then store it in a secure location away from the rest of the CRF.

## Section 2: Details of presenting complaint(s)

What are the relevant presenting complaints for this episode?

# Section 3: Past medical & surgical history

3a – Inflammatory Bowel Disease (IBD) history

Has the participant been previously diagnosed with IBD?

	No	If No, go straight to	Section 3b						
	Yes	If Yes, please indica	If Yes, please indicate which IBD was diagnosed and complete the sub-questions						
		Ulcerative colitis (UC)  a) Extent of disease	please answe E1 - Ulc E2 - Left E3 - Ext	erative pr sided UG ensive UG	octitis (lir C (distal t C (extend	mited to r to splenic	flexure)	enic flexu	re)
		Crohn's disease (plea	s <u>e ans</u> wer sub-	questior	ıs a-e)				
		a) Age at diagnosis	Below 16 Between Above 40 Unknown	17 and 4 ) years o	10 years o Id				
		b) Location of disease	Ileal Croi Colonic ( Ileocoloni Isolated ( Disease	Crohn's ic Crohn upper Gl	disease				
		c) Is there a concomitar	nt upper GI disea	se?	Ye.	s	No	Unkr	nown
		<ul><li>d) Disease behaviour</li><li>e) Is there a concomital</li></ul>	Non-stric Stricturin Penetrati	g ing	on-peneti		No	Unkn	own.
			n penanai diseas	. E		, [	NO	OIIKII	OWII
		Indeterminate colitis ( a) Extent of disease	Proctitis Left side Extensive	(limited to d colitis (d	rectum) distal to s extends p	splenic fle		: flexure)	
		Microscopic colitis Unknown type of IBD							
Date	of dia	ignosis ( <i>nearest month</i>	n and year):	m	m	У	У	У	У

## 3b - Drug history

Please tick to indicate which drug(s) the participant has been prescribed and how long ago it was last taken. Then record the month and year the drug was <u>first</u> prescribed.

NOTE: PARTICIPANT IS **INELIGIBLE** FOR RCT IF ANY BOXES MARKED WITH **[X]** ARE TICKED

	Whe	n drug	s last t	aken							
Drugs list	Never prescribed	In the past (but not last 3m)	In last 3m (but not currently)	Taken for current episode	Date first prescribed						
Oral steroid therapy e.g. prednisolone				*		m	m	У	У	У	У
* [	Duration	of curre	ent stero	id treatr	nent	(days):					
Biological therapies e.g. Infliximab			[X]	[X]		m	m	У	У	У	У
Rosuvastatin (Crestor®)			[X]	[X]		m	m	У	У	У	У
Ciclosporin (Sandimmun <sup>®</sup> , Neoral <sup>®</sup> )			[X]	[X]		m	m	У	У	У	У
<b>Tacrolimus</b> (Prograf <sup>®</sup> / Fujimycin)			[X]	[X]		m	m	У	У	У	У
Azathioprine						m	m	У	У	У	У
Methotrexate						m	m	У	У	У	У
Mercaptopurine (6-MP / Puri-Nethol <sup>®</sup> )						m	m	У	У	У	У
Sulfazalazine						m	m	У	У	У	У
Mesalazine						m	m	У	У	У	У
Other aminosalicylate						m	m	У	У	У	У
(please specify)	(please specify)										

## 3c - Drug allergies

## Does the participant have a history of hypersensitivity to any of the following:

NOTE: PARTICIPANT IS **INELIGIBLE** FOR RCT IF ANY BOXES MARKED WITH **[X]** ARE TICKED

	Yes		No
Infliximab (Remicade <sup>®</sup> )	[X]		
Ciclosporin (Sandimmun <sup>®</sup> / Neoral <sup>® /</sup> Deximune <sup>®</sup> )	[X]		
Polyethoxylated oils	[X]		

## 3d - Co-morbidities

Please indicate which statement is correct by ticking the relevant box.

NOTE: PARTICIPANT IS **INELIGIBLE** FOR RCT IF ANY BOXES MARKED WITH **[X]** ARE TICKED

Ischaemic heart disease (IHD)	[X]	No history IHD but no recent MI Acute MI in last month
Heart failure	[X]	No history  Moderate / severe heart failure
Cerebrovascular disease (CVD) & stroke	[X]	No history CVD but no acute stroke Acute stroke within last month
Respiratory disease	[X]	No history Chronic respiratory disease Respiratory failure
Renal disease	[X]	No history Chronic renal disease Renal failure
Hepatic (liver) disease	[X]	No history Chronic liver disease Hepatic failure
Immunodeficiency	DA	No current diagnosis of immunodeficiency  Current diagnosis of immunodeficiency
Active tuberculosis	IV1	No active / suspected active tuberculosis  Active / suspected active tuberculosis
Severe infection	1	No severe infection

	[X]	Severe infection present
Malignancy	[X]	No current malignancy (excl. BCC)  Current malignancy diagnosed (not including BCC)
Severe cognitive impairment	[X]	No Severe cognitive impairment diagnosed
Diabetes mellitus		No diagnosis of diabetes mellitus  Type 1 diabetes mellitus  Type 2 diabetes mellitus  Other diabetes type e.g. LADA  Diabetes type unknown  Unknown whether participant has diabetes mellitus
Hypertension		No hypertension Participant has hypertension Unknown whether participant has hypertension
Hypercholesterolaemia requiring treatment		No hypercholesterolaemia requiring treatment Participant has hypercholesterolaemia requiring treatment Unknown whether participant has hypercholesterolaemia

## 3e - Previous surgical procedures

Please tick to indicate whether the participant has had any of the following **surgical** procedures? If they have, please record the year of surgery.

Procedures
Colonic surgery
Small bowel surgery
Gastric surgery
Appendicectomy
Cholecystectomy
Open urological surgery
Open gynaecological surgery *

Unknown	No	Yes

If Ye	If Yes, year of surgery									
У	У	У	У							
У	У	У	У							
У	У	У	У							
У	У	У	У							
У	У	У	У							
У	У	У	У							
У	У	У	У							

<sup>\*</sup>Tick "No" if participant is male

# Section 4: Family & social history 4a – Family history

Does the participant have a <b>first degree relative</b> previously diagnosed with an IBD?									
N	lo (If No,	go to Section	4b)						
Y	es If Yes,	please complete	e below						
Please indicate which diagnosis the parent(s) had by <b>ticking</b> in the relevant column.									
Relationship	Ulcerative Colitis	Crohn's disease	Indeterminate colitis	Microscopic colitis	Unknown				
Mother									
Father									
Please enter the <b>nu</b>	umber of siblings a	and children with	a diagnosis of eac	ch IBD in the rele	evant column				
Relationship	Ulcerative Colitis	Crohn's disease	Indeterminate colitis	Microscopic colitis	Unknown				
Sibling(s)									
Child(ren)									
4b – Social history	y								
For each question	n, please indicate	which <b>ONE</b> st	atement is correc	ot:					
4b.i Participant's si	moking status:								
	Current smoker								
	Ex-smoker								
	Non-smoker (his	tory unknown)							
	Never smoked								
	Unknown								
	-								

4b.ii Pre	4b.ii Pregnancy / lactation status:												
Date of p	d	d	m	m	У	У	У	У					
		1											
			Not applicable (participant is female and menstruating / participant is female and post-menopausal / participant is male)										
		Participant not currently pregnant or lactating (MUST be confirmed by nega pregnancy test if of child bearing age and to be considered for RCT)									negative		
	[X]				tly pregr	nant ( <u>Ml</u>	<b>JST</b> be d	confirme	d by pre	gnancy	test		
	[X]	Partic	ipant is	current	tly lacta	ting and	l breasti	feeding					
		1											
4b.iii Par	ticipant's	partici	pation i	n other	clinical	trials:							
		Partici	pant not	in any o	other clin	ical trial	s						
	Participant in another clinical trial(s)												
(If so, please specify which one(s))													
4b.iii Participant's participation in other clinical trials:  Participant not in any other clinical trials  [X]  Participant in another clinical trial(s)													

## Section 5: Baseline clinical data

Please record test results that correspond closest to the date of admission for this episode.

Place a **cross** in the final column if the test was not done (routinely / on this occasion).

5a – Clinical measurements on admission		
Measurement	Result	Test NOT done
		X
Weight	(Kg)	
Height	(m)	
Pulse	(bpm)	
Temperature	(°C)	
Systolic blood pressure	(mm Hg)	
Diastolic blood pressure	(mm Hg)	
5b – blood results on admission		
Haemoglobin	(g/dL)	
Urea	(mmol/L)	
Creatinine	(mmol/L)	
Sodium	(mmol/L)	
Potassium	(mmol/L)	
Chloride	(mmol/L)	
Bicarbonate	(mmol/L)	
C-Reactive protein (CRP)	(mg/L)	
Erythrocyte Sedimentation Rate (ESR)	(mm/hr)	
Alanine transaminase (ALT)	( <i>U/L</i> )	
Aspartate transaminase (AST)	( <i>U/L</i> )	
Alkaline phosphatase (ALP)	( <i>U/L</i> )	
Total bilirubin	(μmol/L)	
Gamma glutamyl transpeptidase (GGT)	( <i>U/L</i> )	
Albumin	(g/L)	
Total cholesterol	(mmol/L)	
Truelove & Witts score (see overleaf)	(range 0-4)	
Glomerular Filtration Rate (GFR)	(mL/min/m²)	

**Calculating the Truelove & Witts score -** 1<sup>st</sup> stage T&W score to be calculated by determining if the patient had bloody stool frequency of 6 or more daily and any one of the following additional criteria:

- pulse >90 bpm;
- haemoglobin <10.5 g/dL;

- temperature >37.8°C;
- ESR >30 mm/hr **or** CRP > 30 mg/L.
- Count the number of additional criteria met by the patient (up to 4) and insert this number as their T&W score.
- o If the patient only has a bloody stool frequency of more than 6 per day, enter "0".
- o If the patient does not have a bloody stool frequency of more than 6 per day, enter "0".

## 5c - Endoscopy performed

Na	Vas an endoscopy performed?											
		Yes										
		No If No, clinical judgement of disease severity:										
		Severe colitis										
	[X]	Not severe	Not severe colitis									
Dat	e of end	oscopy:	d	d	m	m	У	У	У	У		
=n/	losconio	findings:										
_110	JOSCOPIC	illiuliigs.										
	[X]	NORMAL o	NORMAL or inactive disease (score = 0)									
	[X]	MILD: erythema, decreased vascularity, mild friability (score = 1)										
		MODERATE	MODERATE: marked erythema, absent vascularity, friability, erosions (score = 2)									
		SEVERE: S	pontaneou	us bleedin	ıg, ulcerat	ion (sco	re = 3)					
		1										

#### 5d - Stool culture results

Please indicate which	of the fo	llowing	staten	nents is	correct	t:				
Stool culture normal (negative for infection)										
Growth	n on stool	(see no	tes belo	ow)						
Date of stool culture res	sults:	d	d	m	m	У	У	У	У	
Growth identified as:	[X]	Camn								
Growth identified as.	[X]	Campylobacter on stool culture Salmonella on stool culture								
	[X]	Shigella on stool culture								
		C difficile								
		C difficile on stool culture								
		C difficile on toxin ELISA (see note #3 below)								
		Number of positive toxin ELISA tests								
	[X]	Cytomegalovirus (CMV) on stool culture								
	[X]	Amoe	biasis	on stoo	l cultur	е				
	[X]	Uncla	Inclassified / other infection (please specify)							
		<b>.</b> ——								
		Equivocal stool test result (please give details)								
		_								

#### **NOTES:**

- 1) If the participant is proven to have <u>infective colitis with NO evidence of any other IBD</u>, they must be excluded from the cohort study by completing the **Cohort Exclusion Form**.
- 2) If the participant has infective colitis <u>alongside</u> another IBD, they may remain in the cohort.
- 3) A positive *C difficile* result on ELISA can be overridden by a clinical decision if the test is considered unreliable (see Section 5f). *C difficile* on stool culture excludes the patient from the RCT.

## 5e – Histology results

Please indicate which o	f the thre	ee followi	ng stater	nent	s is c	orrect:			
Histology I	Histology not done – participant known to have ulcerative colitis (go to Section 5f)								
<sup>[X]</sup> Histology	Histology reported as normal								
Abnormalities reported on histology									
Date of histology results:	d	d	m	r	n	У	У	У	У
Abnormality reported	l as:								
	Ulcerativ	e colitis							
[X]	Crohn's	disease							
	Indeterm	inate colit	is which is	S		CI	inically ul	cerative o	colitis
						[X] CI	inically (	Crohn's c	lisease
[X]	Cytomeg	galovirus	(CMV) co	olitis					
[X]	Microscopic colitis								
[X]	Other histology results (please specify)								

5f – Clinical conclusion after all test results received							
Conclusion:		UC only – no other abnormal test results					
		UC + results that do not exclude from RCT (e.g. C diff on ELISA)					
	[X]	UC + infection that excludes from RCT					
	[X]	UC + other cause of exclusion from RCT (e.g. age <18y, pregnancy, etc)					
	[X]	Other IBD (not UC)					
	[X]	Infective colitis only					
	[X]	Other non-IBD diagnosis (specify)					

Please fax all pages completed so far to 01792 606599 as soon as possible.

# Section 6: Progress (after 2 days IV steroid treatment)

**NOTE**: When entering data onto GeneCIS, Section 6 of the Cohort CRF: *Progress (after 2 days of IV steroids)* can be found on the separate questionnaire: '04 - Cohort Progress'



After 2 days treatment with intravenous (IV) hydrocortisone, a decision should be made regarding the participant's response.

regarding the participant of responses.									
6a – Steroid treatment									
6a.i Has IV hydrocortisone treatment been initia	ited at	any p	oint fo	ollowi	ng ad	missio	on?		
No Go to Section 6b									
Yes									
Date IV steroid therapy initiated:	d	d	m	m	У	У	У	У	
Time IV steroid therapy initiated:	h	h	m	m	(using 24h clock)				
Date of transfer from IV to oral steroids:	d	d	m	m	У	У	У	У	
Date of decision regarding response to IV steroids:	d	d	m	m	У	У	У	У	
Ga.ii Participant's response to IV hydrocortisone treatment:  Good response within approx 2-5 days  Truelove & Witts score on day 5 / at discharge (whichever is sooner):  Inadequate response within approx 2-5 days  Criteria for non-response decision:  Stool frequency >8 per day  Stool frequency of 3-8 per day with CRP > 45mg/L  Clinical judgement (state basis for opinion)									

treatment?										
	No - COHORT CRF COMPLETED									
[X]	Yes									
	_	Which ty	pe of surgery was performed	:						
			Panproctocolectomy							
			Subtotal colectomy							
			lleoanal pouch with stoma							
			lleoanal pouch without stoma							
			Formation of ileostomy							
			Other surgical procedure (p	lease state)						
	_									
		-								

Is clinical judgement that the participant requires a colectomy without further medical

#### You have now reached the end of the Cohort CRF.

6b - Surgery

Date of surgery:

Please fax all pages to the CONSTRUCT Trial Office on 01792 606599 as soon as possible. If some information is outstanding, please record it as soon as possible and refax that page.

NOTE: If participant is still potentially eligible for the RCT at this point (i.e. no exclusion criteria [X] have been recorded on this Cohort CRF), please complete an **RCT Screening Form** using the responses to the eligibility questions on this CRF.